Afutuzumab is a monoclonal antibody designed for therapeutic use, primarily targeting the CD20 antigen found on the surface of B cells. This characteristic makes it particularly relevant in the treatment of certain hematological malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. As a humanized IgG1 antibody, Afutuzumab is engineered to enhance its efficacy and reduce immunogenicity compared to murine antibodies. Its mechanism of action involves binding to CD20, leading to the destruction of B cells through various immune-mediated processes, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The pharmacokinetics of Afutuzumab typically involve a prolonged half-life, allowing for less frequent dosing regimens. Safety profiles indicate common adverse effects associated with monoclonal antibodies, such as infusion reactions and potential immunosuppression. Overall, Afutuzumab represents a significant advancement in targeted therapies for B-cell malignancies, contributing to improved patient outcomes in oncology.

Afutuzumab

949142-50-1: Afutuzumab is a monoclonal antibody designed for therapeutic use, primarily targeting the CD20 antigen found on the surface of B cells. This characteristic makes it particularly relevant in the treatment of certain hematological malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. As a humanized IgG1 antibody, Afutuzumab is engineered to enhance its efficacy and reduce immunogenicity compared to murine antibodies. Its mechanism of action involves binding to CD20, leading to the destruction of B cells through various immune-mediated processes, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The pharmacokinetics of Afutuzumab typically involve a prolonged half-life, allowing for less frequent dosing regimens. Safety profiles indicate common adverse effects associated with monoclonal antibodies, such as infusion reactions and potential immunosuppression. Overall, Afutuzumab represents a significant advancement in targeted therapies for B-cell malignancies, contributing to improved patient outcomes in oncology.

<p>Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.</p>

Obinutuzumab

<p>Activates B-cell apoptosis; treatment of B-cell malignancies</p>

CAS 949142-50-1

Afutuzumab

Obinutuzumab

Ref: TM-T9924

Obinutuzumab - Buffer solution

Ref: 3D-BO165592